RHYTHM PHARMACEUTICALS, INC. Amortization of Intangible Assets
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Amortization of Intangible Assets of $855.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2024-02-29
- RHYTHM PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2023-03-31 was $214.00K, a 64.62% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2022-12-31 was $214.00K, a 87.72% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2022-09-30 was $214.00K, a 87.72% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2022-06-30 was $216.00K, a 89.47% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2023 was $855.00K, a 10.47% increase from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2022 was $774.00K, a 126.32% increase from fiscal 2021.
- RHYTHM PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2021 was $342.00K.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2023-12-31 | $855.00K 10-K · filed 2024-02-29 | |||
| 2023-03-31 | $214.00K 10-Q · filed 2023-05-02 | $428.00K derived: sum of 2 quarters · filed 2024-02-29 | $642.00K derived: sum of 3 quarters · filed 2024-02-29 | $858.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-12-31 | $214.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $428.00K derived: sum of 2 quarters · filed 2024-02-29 | $644.00K derived: sum of 3 quarters · filed 2024-02-29 | $774.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $214.00K 10-Q · filed 2022-11-08 | $430.00K derived: sum of 2 quarters · filed 2022-11-08 | $560.00K 10-Q · filed 2022-11-08 | $674.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $216.00K 10-Q · filed 2022-08-03 | $346.00K 10-Q · filed 2022-08-03 | $460.00K derived: sum of 3 quarters · filed 2024-02-29 | $574.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $130.00K 10-Q · filed 2023-05-02 | $244.00K derived: sum of 2 quarters · filed 2024-02-29 | $358.00K derived: sum of 3 quarters · filed 2024-02-29 | $472.00K derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $114.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $228.00K derived: sum of 2 quarters · filed 2024-02-29 | $342.00K derived: sum of 3 quarters · filed 2024-02-29 | $342.00K 10-K · filed 2024-02-29 |
| 2021-09-30 | $114.00K 10-Q · filed 2022-11-08 | $228.00K derived: sum of 2 quarters · filed 2022-11-08 | $228.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $114.00K 10-Q · filed 2022-08-03 | $114.00K 10-Q · filed 2022-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |